Lonza, Basel, Switzerland, has signed an exclusive license agreement with Berlin, Germany-based ORGANOBALANCE for the global development, production and commercialization of products containing a probiotic Lactobacillus strain. Developed by ORGANOBALANCE GmbH via a fermentation process, the probiotic strain acts against Helicobacter pylori (H. pylori). Research shows that H. pylori has been implicated as a common cause of peptic ulcers and gastritis.

Utilizing a unique patent-protected mode of action, Lactobacillus anti-H. pylori binds to H. pylori in the stomach, thus creating large aggregates, which are subsequently flushed out of the stomach and excreted.